Ram Gordon, MD
Interventional Cardiology · Fairfield, CTNPI 1295718252
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,600 of the $10,513 with a category attached, or 91.3%. Amgen accounts for 98.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $10,444 and has fallen 99.7% since, to $32 in 2024.
Across 43 payments — averaging $244.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- E.r. Squibb & Sons, L.L.C.$122
- Heartflow, Inc.$36
- Philips North America LLC$32
What the payments were for
- Speaking & faculty fees$9,60091%
- Travel & lodging$1101%
- Food & beverage$8028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $10,322 |
| E.r. Squibb & Sons, L.L.C. | 15 | $122 |
| Heartflow, Inc. | 1 | $36 |
| Philips North America LLC | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$9,954
How this compares
$10,513 in reported general payments places this provider in the 65th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 658 | $799,187 |
| VyndamaxTafamidis | 29 | $624,552 |
| XareltoRivaroxaban | 196 | $231,416 |
| FarxigaDapagliflozin Propanediol | 87 | $112,920 |
| EntrestoSacubitril/Valsartan | 55 | $80,879 |
| Repatha SureclickEvolocumab | 78 | $68,491 |
| MultaqDronedarone Hcl | 25 | $34,991 |
| VascepaIcosapent Ethyl | 24 | $19,052 |
| Rosuvastatin Calcium | 1,384 | $16,607 |
| Nebivolol Hcl | 165 | $13,159 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 305 | $10,905 |
| Metoprolol Succinate | 750 | $10,671 |
| Valsartan | 419 | $9,044 |
| Ezetimibe | 280 | $7,953 |
| Varenicline Tartrate | 28 | $7,624 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Fairfield
- Matthew SeigermanFairfield$5K
- Edward TuohyFairfield$4K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
- Sarfaraz MemonHartford$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.